# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN-TD
- Date: 2001-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thandiwe Mokoena, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for first visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referral. **S**

## Objective

PSA: 6.4 ng/mL (high); Total testosterone: 412 ng/dL; Hemoglobin: 14.1 g/dL; White cell count: 5.8 10*3/uL; Platelets: 226 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Fasting glucose: 94 mg/dL; Creatinine: 1.08 mg/dL; eGFR: 69 mL/min/1.73 m²; Calcium: 9.4 mg/dL; ALT: 18 U/L; Alkaline phosphatase: 74 U/L; Albumin: 4.1 g/dL; Hemoglobin A1c: 5.5%; Total cholesterol: 184 mg/dL; HDL cholesterol: 52 mg/dL; LDL cholesterol: 112 mg/dL; Triglycerides: 98 mg/dL; 25-hydroxyvitamin D: 26 ng/mL (low); PHQ-9: 4; IPSS total (0 to 35): 7. All results are synthetic.

BP 132/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 80.2 kg; BMI 23.9 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer; Hormone-sensitive prostate cancer. Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Radiation oncology consultation to review staging and discuss curative treatment options and short-term androgen deprivation. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022) **S**
- Staging for unfavorable intermediate-risk disease with PSMA PET/CT. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**
- Distress screening at each visit, physical activity, and a written survivorship care plan. Guideline: Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**
